Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.

(2017) C. Gambacorti-Passerini et al.   JOURNAL OF CLINICAL ONCOLOGY

Approach to diabetes management in patients with CVD

(2016) Sanam Lathief et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System

(2015) Jorge Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

(2015) G. Gugliotta et al.   HAEMATOLOGICA

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

(2015) G. Gugliotta et al.   HAEMATOLOGICA

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

(2015) Preetesh Jain et al.   Lancet Haematology

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

(2014) Carlo Gambacorti-Passerini et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

(2014) Carlo Gambacorti-Passerini et al.   AMERICAN JOURNAL OF HEMATOLOGY

First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis

(2014) Ilaria Viganò et al.   AMERICAN JOURNAL OF HEMATOLOGY

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

(2014) P. Valent et al.   BLOOD

Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

(2014) Tim H. Brümmendorf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

(2014) H. Jean Khoury et al.   LEUKEMIA & LYMPHOMA

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

(2013) H. M. Kantarjian et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis

(2013) Preetesh Jain et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors

(2013) D. J. Lenihan et al.   ONCOLOGIST

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes

(2013) Kimberly R. Doherty et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

(2012) H. J. Khoury et al.   BLOOD

Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

(2012) David Montani et al.   CIRCULATION

Nilotinib-Associated Vascular Events

(2012) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

(2012) Baichun Yang et al.   JOURNAL OF APPLIED TOXICOLOGY

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

(2012) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

(2011) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Systematic review on evidence of the effectiveness of cholesterol-lowering drugs

(2010) Abhaya Gupta et al.   ADVANCES IN THERAPY

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

(2010) Faye M. Johnson et al.   CANCER

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

(2010) F J Giles et al.   LEUKEMIA

Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

(2008) David L. DeRemer et al.   CLINICAL THERAPEUTICS

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA